RVMD REVOLUTION MEDICINES INC revenue, earnings and financials

For the quarter ended June 30, 2026, REVOLUTION MEDICINES INC reported revenue of n/a, net income of −$644M and diluted EPS of −$3.06; for the fiscal year ended December 2025 revenue was $0.

RVMD annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $0, gross profit n/a, operating income −$1.18B, net income −$1.13B (margin n/a), EPS −$5.95
• Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$690M, net income −$600M (margin n/a), EPS −$3.58
• Fiscal year ended Dec 2023: revenue $11.6M, gross profit n/a, operating income −$487M, net income −$436M (margin -3765.1%), EPS −$3.86
• Fiscal year ended Dec 2022: revenue $35.4M, gross profit n/a, operating income −$258M, net income −$249M (margin -703.8%), EPS −$3.08
• Fiscal year ended Dec 2021: revenue $29.4M, gross profit n/a, operating income −$188M, net income −$187M (margin -636.3%), EPS −$2.57

RVMD quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue n/a, net income −$644M, EPS −$3.06
• Quarter ended Mar 31, 2026: revenue n/a, net income −$454M, EPS −$2.29
• Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$365M, EPS −$1.90
• Quarter ended Sep 30, 2025: revenue n/a, net income −$305M, EPS −$1.61
• Quarter ended Jun 30, 2025: revenue n/a, net income −$248M, EPS −$1.31
• Quarter ended Mar 31, 2025: revenue n/a, net income −$213M, EPS −$1.13
• Quarter ended Dec 31, 2024 (from the annual report): revenue $0 (down 100.0% year over year), net income −$194M, EPS −$1.13
• Quarter ended Sep 30, 2024: revenue $0, net income −$156M, EPS −$0.94
• Quarter ended Jun 30, 2024: revenue $0 (down 100.0% year over year), net income −$133M, EPS −$0.81
• Quarter ended Mar 31, 2024: revenue $0 (down 100.0% year over year), net income −$116M, EPS −$0.70
• Quarter ended Dec 31, 2023 (from the annual report): revenue $742K (down 95.2% year over year), net income −$161M, EPS −$1.23
• Quarter ended Sep 30, 2023: revenue $0 (down 100.0% year over year), net income −$108M, EPS −$0.99
• Quarter ended Jun 30, 2023: revenue $3.82M (down 58.1% year over year), net income −$98.3M, EPS −$0.92
• Quarter ended Mar 31, 2023: revenue $7.01M (down 7.4% year over year), net income −$68.1M, EPS −$0.72
• Quarter ended Dec 31, 2022 (from the annual report): revenue $15.3M (up 62.1% year over year), net income −$56.8M, EPS −$0.61
• Quarter ended Sep 30, 2022: revenue $3.36M (up 204.8% year over year), net income −$73.3M, EPS −$0.87
• Quarter ended Jun 30, 2022: revenue $9.12M (up 4.8% year over year), net income −$61.2M, EPS −$0.82
• Quarter ended Mar 31, 2022: revenue $7.58M (down 25.2% year over year), net income −$57.6M, EPS −$0.78
• Quarter ended Dec 31, 2021 (from the annual report): revenue $9.46M, net income −$52.6M, EPS −$0.72
• Quarter ended Sep 30, 2021: revenue $1.10M, net income −$52.9M, EPS −$0.72

RVMD cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$898M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$557M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$351M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$224M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$147M, share buybacks n/a

RVMD balance sheet

• Jun 30, 2026: cash $815M, total assets $4.32B, total liabilities $1.72B, shareholders' equity $2.61B
• Mar 31, 2026: cash $441M, total assets $2.25B, total liabilities $754M, shareholders' equity $1.50B
• Dec 31, 2025: cash $384M, total assets $2.35B, total liabilities $723M, shareholders' equity $1.63B
• Sep 30, 2025: cash $217M, total assets $2.25B, total liabilities $655M, shareholders' equity $1.60B
• Jun 30, 2025: cash $402M, total assets $2.43B, total liabilities $564M, shareholders' equity $1.87B
• Mar 31, 2025: cash $334M, total assets $2.37B, total liabilities $287M, shareholders' equity $2.08B
• Dec 31, 2024: cash $543M, total assets $2.56B, total liabilities $293M, shareholders' equity $2.27B
• Sep 30, 2024: cash $201M, total assets $1.76B, total liabilities $197M, shareholders' equity $1.57B

What is RVMD's revenue?

REVOLUTION MEDICINES INC reported $0 of revenue for the fiscal year ended December 2025.

Is RVMD profitable?

No. REVOLUTION MEDICINES INC lost $1.77B over the last four quarters.

What is RVMD's EPS?

Diluted earnings per share over the last four quarters were −$8.86; −$3.06 in the latest quarter.

RVMD ownership and insider trades · All stocks